Who are Salmeterol Discus 50 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xolaam®, Formoterol fumerate, Arformoterol (Brovana), long acting beta agonist, vilanterol (VI), Servent Diskus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/salmeterol-discus-50-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Salmeterol Discus 50 µg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Salmeterol Discus 50 µg (Salmeterol Discus 50 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist (LABA). Area: Respiratory.

phase 3 Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol Discus 50 µg (Salmeterol Discus 50 µg) — AstraZeneca. Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Salmeterol Discus 50 µg TARGET	Salmeterol Discus 50 µg	AstraZeneca	phase 3	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor (ADRB2)
Xolaam®	Xolaam®	AstraZeneca	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor
Formoterol fumerate	Formoterol fumerate	Novartis	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor
Arformoterol (Brovana)	Arformoterol (Brovana)	Trinity Health Of New England	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor
long acting beta agonist	long acting beta agonist	University of Alberta	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor
vilanterol (VI)	vilanterol (VI)	GlaxoSmithKline	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor (ADRB2)
Servent Diskus	Servent Diskus	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist (LABA) class)

GlaxoSmithKline · 8 drugs in this class
AstraZeneca · 5 drugs in this class
Novartis · 3 drugs in this class
Sumitomo Pharma America, Inc. · 3 drugs in this class
Chiesi Farmaceutici S.p.A. · 3 drugs in this class
Organon and Co · 2 drugs in this class
Fundacio Privada Mon Clinic Barcelona · 2 drugs in this class
Henan University of Traditional Chinese Medicine · 1 drug in this class
Genentech, Inc. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol Discus 50 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-discus-50-g. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab